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Abstract: The management of COPD is complex and patient adherence to treatment 
recommendations is known to be poor. In this paper the methods used for evaluating adherence 
in COPD are compared. Self-reporting has satisfactory reliability and offers a cheap, simple 
and easy method for assessing adherent behaviors. Unlike the objective measures of adherence 
such as electronic monitoring, self-reporting helps in identifying the reasons for nonadherence, 
which in turn would be useful in addressing adherence issues. 
Patients do not follow their treatment recommendations either intentionally or uninten-
tionally. Intentional deviations are driven by patient beliefs and experiences about illness and 
treatment, which are in turn inﬂ  uenced by social and cultural factors. Unintentional deviations 
are often due to cognitive impairment and lack of routines. Factors associated with adherence 
in COPD have been explained using the Becker-Maiman model.
Strategies for overcoming nonadherence have to be formulated based on the nature and 
reasons for nonadherence. In the event of unintentional nonadherence, the use of adherence aids 
like Dosette boxes, calendar packs and reminders should be promoted. Understanding patient 
beliefs and experiences, patient education focusing on the pathology of COPD and the role of 
treatment, periodic monitoring and reinforcement are critical for overcoming the barriers of 
intentional nonadherence.
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Introduction
Chronic obstructive pulmonary disease (COPD) is and will continue to be a major 
public health problem in both developed and developing countries (Murray and 
Lopez 1996, 1997; WHO 2004). Progressive introduction of pharmacologic, non-
pharmacologic and surgical treatments are often necessary to cope with the deteriorating 
respiratory function in COPD (Pauwels et al 2001). Treatment effectiveness in any 
condition depends not only on the appropriateness of the drugs prescribed and/or the 
recommendations given, but also on patient commitment to the intended treatment 
(Marinker et al 1997). Failure to take medicines as intended or deviations from recom-
mended management might result in therapeutic failure as well as wastage of health 
resources (McKenney and Harrison 1976; Col et al 1990; Stanton et al 1994; Howard 
et al 2003). Health professionals may be unaware of their patients’ drug utilization 
patterns and may underestimate the effectiveness of drug regimens, in turn leading to 
prescribing errors (Mellins et al 1992). The importance of patient commitment for the 
success of COPD management programs is well recognised (Pauwels et al 2001).
The extent to which a person’s behavior (in terms of taking medications, follow-
ing diets, or executing lifestyle changes) coincides with medical or health advice was 
labeled as ‘compliance’ in late 1970s (Haynes et al 1979). In the modern era patient 
rights not to follow the medical advice is well recognized and ‘compliance’ is regarded 
to be politically incorrect. It is increasingly being replaced with ‘adherence’, which is International Journal of COPD 2007:2(3) 254
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less judgmental and more respectful of the role that patients 
can play in their own treatment (Marinker et al 1997). Devia-
tions from clinical prescriptions or recommendations have 
been evaluated quantitatively and qualitatively. Quantitative 
deﬁ  nitions for medication adherence often refer to the extent 
of those deviations and include amount of medicine taken 
over a given time period, or to the extent of its correlation 
with aspects such as the recommended timing of the medica-
tion, the intended duration of the treatment and the recom-
mended method of administration (Marinker et al 1997). 
Based on the extent of utilization, three patterns of medication 
nonadherence – viz ‘underutilization’, ‘over utilization’ and 
‘inappropriate use’ have been reported (Dolce et al 1991). 
In a meta-analysis of studies reporting adherence to medical 
treatment, the average nonadherence rate was found to be 
24.8% (DiMatteo 2004).
Qualitative deﬁ  nitions refer to variables such as intention-
ality, memory and health beliefs that result in deviations from 
the recommended treatment (Marinker et al 1997). Devia-
tions from treatment recommendations could be intentional 
and/or unintentional. ‘Unintentional nonadherence’ may be 
due to simple forgetfulness, or inability to follow treatment 
instructions because of poor understanding or physical prob-
lems such as poor eyesight or dexterity problems (Marinker 
et al 1997). ‘Intentional nonadherence’ arises when the 
patient rejects either the doctor’s diagnosis or the doctor’s 
recommended treatment (Horne 1997; Marinker et al 1997). 
The latter is often a rational decision made by the patient to 
reject either the diagnosis or the recommended treatment 
after careful consideration of the perceived risks/costs 
versus beneﬁ  ts and has been called ‘intelligent nonadherence’ 
(Weintraub 1990). It is often driven by patient beliefs and 
experiences about illness and treatment, which are in turn 
inﬂ  uenced by social and cultural factors. This paper gives 
an overview of adherence research in COPD with a focus 
on the methods employed for studying adherence and the 
factors associated with adherent behavior.
A literature search using OVID and International Pharma-
ceutical Abstracts (IPA) was performed with the following 
terms: (COPD OR bronchitis OR emphysema) AND (adher-
ence OR compliance OR concordance). Relevant articles 
were selected after reviewing the abstracts.
Adherence in COPD
Adherence to both pharmacological and non-pharmacological 
management is critical for optimal outcomes in patients 
with COPD (Pauwels et al 2001). Good medication adher-
ence was associated with both decrease in the number 
of hospitalizations and length of hospital stay among 
patients with chronic respiratory ailments (Balakrishnan 
and Christensen 2000). It would be reasonable to assume 
that in a symptomatic disease with progressive decline in 
quality of life such as COPD, patients would strictly follow 
the medical advice. However, in a meta analysis of adher-
ence studies, the mean adherence to medical treatment in 
pulmonary diseases was found to be only 68.8% (DiMatteo 
et al 2002), which was much less compared to mean adher-
ence in other chronic disease conditions. Nonadherence 
in COPD is a multi-dimensional quandary and includes 
short and long-term medication nonadherence (Chryssidis 
et al 1981; Taylor et al 1984; James et al 1985; Dolce et al 
1991; Dompeling et al 1992; Rand et al 1992, 1995; Turner 
et al 1995; Bosley et al 1996; Hatton et al 1996; Pepin 
et al 1996; Simmons et al 1996, 2000; Corden et al 1997; 
Gallefoss et al 1999; Balakrishnan and Christensen 2000; van 
Grunsven et al 2000), nonadherence to life style changes such 
as smoking cessation (James et al 1985; Rand et al 1995; 
Turner et al 1995; Gallefoss et al 1999; Young et al 1999; 
Mapel et al 2000; Simmons et al 2000), non-participation 
in or early withdrawal from respiratory rehabilitation or 
exercise programs (Young et al 1999; Emery et al 2003; 
Arnold et al 2006), failure to meet vaccination requirements 
(Fox et al 1995; Nichol et al 1999; Garcia-Aymerich et al 
2000), missing scheduled clinic or home visits (Turner et al 
1995; Hatton et al. 1996), and inadequate monitoring of 
treatment response (Gallefoss et al 1999). Underutilization 
(Taylor et al 1984; James et al 1985; Dolce et al 1991; Dompeling 
et al 1992; Hatton et al 1996), overutilization (Chryssidis 
et al 1981; James et al 1985; Dolce et al 1991; Pepin et al 
1996) and inappropriate use (Allen and Prior 1986; 
Horsley and Bailie 1988; Dolce et al 1991; Dompeling 
et al 1992; Chapman et al 1993; Nimmo et al 1993; Gray 
et al 1994, 1996; Thompson et al 1994; van Beerendonk et al 
1998; Johnson and Robart 2000; van Grunsven et al 2000) of 
medications have been reported among patients with COPD. 
Poor adherence to drug therapy and disease management 
programs has been identiﬁ  ed as the major factor resulting 
in emergency hospitalization among COPD patients (Col 
et al 1990; Fuso et al 1995; Garcia-Aymerich et al 2000).
Adherence evaluation in COPD 
Various direct and indirect methods have been used for 
evaluating treatment adherence in COPD. The majority of 
the adherence studies have been carried out from the health 
professionals’ perspective with little regard for the perspec-
tive of patients. Wide variation exists in the deﬁ  nitions, International Journal of COPD 2007:2(3) 255
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classiﬁ  cations and ‘cut-off values’ for optimal adherence in 
different studies. Each method has its own limitations and 
advantages. Wide variations were observed in the extent of 
nonadherence reported among COPD patients, based on the 
deﬁ  nition of adherence used, the method of assessment, the 
focus characteristic chosen for adherence assessment, ‘cut-off 
values’ for classiﬁ  cation as adherent or nonadherent, patient 
population, time of assessment, and duration of follow-up. An 
overview of the various methods used for assessing adherence 
in COPD is given in Table 1.
Few researchers have used multiple methods or tools to 
study adherence in their study population and compared the 
results (Taylor et al 1984; Dolce et al 1991; Dompeling et al 
1992; Rand et al 1992, 1995; Nides et al 1993; Bosley et al 
1995; Simmons et al 2000). Self-reporting of missed doses 
underestimated nonadherence when compared to more objec-
tive measures such as capsule count (Dompeling et al 1992), 
inhaler weights (Rand et al 1995) and electronic monitoring 
(Rand et al 1992; Braunstein et al 1996; Simmons et al 2000). 
Self-report had moderate reliability (25%–67%) when com-
pared against more objectives measures of adherence such as 
canister weight (Rand et al 1995) and electronic monitoring 
(Gong et al 1988; Nides et al 1993; Bosley et al 1995). Being 
aware of monitoring of medication adherence using objective 
methods such as electronic monitoring might encourage some 
patients to exaggerate their self-reported adherence (Spector 
et al 1986). Awareness of monitoring device or feedback on 
monitoring results might improve patient adherence with the 
medication(s) under surveillance (Nides et al 1993; Turner 
et al 1995), but at the same time patients could be nonadherent 
with any medications unmonitored (Turner et al 1995).
Electronic monitors provide more objective and reli-
able information on adherence than any other measures of 
adherence that are currently available. However, they are 
useful only to detect the presence of a problem (nonadher-
ence); they are unable to ﬁ  nd the cause of the problem. For 
example, intentional nonadherence (such as steroid phobia) 
cannot be differentiated from unintentional nonadherence 
(eg, forgetfulness). Hence electronic monitors are not 
helpful in ﬁ  nding solutions for the issue, even if detected. 
Moreover, the feasibility and cost effectiveness of electronic 
monitoring in routine clinical practice are doubtful (Gong 
et al 1988). In the era of ‘concordance’ where adherence 
is assumed to be the joint responsibility of the patient and 
health professionals, the use of such devices without patient 
knowledge is unethical and might even disrupt the mutual 
relationship between the health professionals and patients. 
Currently electronic monitors are not available for all the 
available dosage forms (eg, strip-packed tablets). Electronic 
monitoring cannot ensure that the medication withdrawn 
from the container had actually been consumed. Technical 
problems like battery failure or data retrieval problems have 
been shown to result in loss of adherence data, suggesting 
that researchers should not depend entirely on electronic 
monitors for monitoring adherence (Gong et al 1988; Nides 
et al 1993; Braunstein et al 1996; Simmons et al 1996, 1998, 
2000). Self-report of nonadherence has been shown to have 
satisfactory reliability among patients with COPD, when 
veriﬁ  ed against objective measures (Dolce et al 1991; Nides 
et al 1993; Rand et al 1995). Overestimation of adherence 
and poor reliability are common criticisms about self-reports; 
however, people who report nonadherence are likely to tell 
the truth (Haynes et al 1980; Inui et al 1981; Choo et al 1999; 
Erickson et al 2001).
Very few studies have incorporated inhalation technique 
assessment into the medication adherence evaluation process 
(Dolce et al 1991; Dompeling et al 1992; Turner et al 1995). 
Inhalation techniques have been assessed using checklists 
adapted from guidelines set by different professional orga-
nizations (Allen and Prior 1986; Armitage and Williams 
1988; Horsley and Bailie 1988; Dolce et al 1991; Dompeling 
et al 1992; Chapman et al 1993; Nimmo et al 1993; Gray 
et al 1994, 1996; Thompson et al 1994; van der Palen et al 
1995, 1999; van Beerendonk et al 1998; Johnson and Robart 
2000). Only few researchers have assessed the total inhaler 
technique (Horsley and Bailie 1988; Dompeling et al 1992; 
Connolly 1995), while others categorized the steps in the 
inhalation process into ‘key’ or ‘essential’ and ‘non-essential’ 
steps and assessed only those ‘critical steps’.(Dompeling 
et al 1992; van der Palen et al 1995, 1999; van Beerendonk 
et al 1998) Multiple raters (up to ﬁ  ve) were involved in the 
assessment process in some studies (Allen and Prior 1986; 
Chapman et al 1993) and the poor inter- and intra-rater 
reliability reported among the raters (Allen and Prior 1986; 
Chapman et al 1993; Gray et al 1994), even for the ‘critical 
steps’, is a concern (Gray et al 1994). Some of the newer 
devices incorporate a ﬂ  ow sensor which has the capability 
to track the actual dose inhaled. Even ‘objective monitoring’ 
could detect only one of the problems associated with inhala-
tion technique, ie, inadequate respiratory volume following 
canister actuation (Chapman et al 1993).
Factors associated with adherence 
in COPD
Patients with COPD have many potential risk factors for 
nonadherence. COPD being a disease condition characterized International Journal of COPD 2007:2(3) 256
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Table 1 Methods for studying adherence in patients with chronic respiratory disease
Method Description  Features
Indirect methods
Inhaler weights(Chryssidis et al 1981;  Patients are asked to produce all their  Patients might fail to produce all the used canisters; does not
Rand et al 1992, 1995;  used inhaled medication canisters at  reﬂ  ect adherence distribution over time; difﬁ  cult to distinguish
Nides et al 1993;  the time of clinic or home visit, which   ‘test’ puffs from inhaled puffs; unable to identify ‘overﬁ  lls’ in the
Braunstein et al 1996;  are weighed using a balance with high  canister leading to wrong ﬁ  ndings; deliberate canister emptying
Simmons et al 2000)  sensitivity and precision.  prior to follow-up is possible; weighing the canisters is   
   inconvenient. 
Self-report on medication utilization  Patients are asked speciﬁ  c questions   Patients might overestimate adherence to impress their health
(James et al 1985;  about the drug usage pattern such as   professionals; limited by patients’ ability to recall the events.
Dolce et al 1991;  doses missed, prescribed and used 
Dompeling et al 1992;  doses in the past or over a deﬁ  nite 
Rand et al 1992, 1995;  time period.
Turner et al 1995;
Braunstein et al 1996;
Incalzi et al 1997;
Garcia-Aymerich et al 2000;
Simmons et al 2000)
Medication adherence questionnaire  Speciﬁ  c questions on intentional and  Does not include all the factors inﬂ  uencing adherence; some
(Morisky et al 1986;  unintentional deviations from the  questions could be confusing for patients on respiratory 
Dolce et al 1991;  recommended management eg, Morisky’s  medications to be used on a ‘when needed’ (prn) basis; 
Horne 1996;  scale (Morisky et al 1986) or its modiﬁ  ca-  reliability needs to be tested in individual patient populations.
Svarstad et al 1999;  tions, and the Medication Adherence 
George et al 2005, 2006b)  Report Scale (MARS) (Horne 1996).
Electronic monitoring eg, Datalogger,  Microprocessors or data-loggers  Expensive; could be obtrusive; unethical to use without prior
Chronolog, clock counters, MEMS  record the date and time of medication   information to patients; could alter the natural adherence
(medication event monitoring system)  use events, such as opening the cap of a   pattern in patients who are aware of the technology; conﬁ  rms
cap (Spector et al 1986;  bottle or release of medication   only medication withdrawal not administration; cannot identify
Gong et al 1988;  from the container.  multiple medication withdrawal of solid dosage forms; monitor
Bosley et al 1996;    might dysfunction; not available for adherence assessment of all
Braunstein et al 1996;    dosage forms; helpful in identifying dose dumping; more suitable
Pepin et al 1996;    for use in clinical trial settings than for routine clinical purposes.
Simmons et al 1996, 1998, 2000;
Corden et al 1997;
Lin et al 2006)
Inhalation technique assessment  Assessment of inhalation technique   Rater assessments are subjective; depends on the expertise of
(Allen and Prior 1986;  by one or more raters or objective   rater(s); possibility of high inter- and intra-rater variability; utili-
Horsley and Bailie 1988;  rating using a ﬂ  ow sensor.  zation pattern in real life might be different to that during dem-
Dolce et al 1991;    onstration to the raters; should be combined with other
Dompeling et al 1992;    measures to study medication taking behavior.
Chapman et al 1993;
Nimmo et al 1993;
Gray et al 1994, 1996;
Thompson et al 1994;
van Beerendonk et al 1998;
Johnson and Robart 2000)
Medication or pill count  Patients are asked to produce their  Intrusive; tedious process especially with multiple medications;
(Dompeling et al 1992;  medications during the clinic or   does not reﬂ  ect adherence distribution over time; patients   
van Grunsven et al 2000)  home visit,  might forget to bring in used medication containers; could dump
  which are counted.  medications before clinic visit.
Pharmacy reﬁ  ll data or claims   Medication reﬁ  ll histories or purchase   Patients might not take their drugs despite having the prescrip-
data (Taylor et al 1984;  data from pharmacies or claims data   tions reﬁ  lled; might not reﬂ  ect the actual medication utilization
Spector et al 1986;  from the insurer.  (can hoard drugs); collection of information could be limited by
Kelloway et al 1994;    privacy legislation; useful only for prescription medications;
Gallefoss et al 1999;    assessment is difﬁ  cult in patients with multi-pharmacy patronage.
Balakrishnan and Christensen 2000)
(Continued)International Journal of COPD 2007:2(3) 257
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Table 1(Continued)
Method Description Features
Daily diary  Patients record their daily medication   Vulnerable to patient deceit; patients might forget to ﬁ  ll in
(Spector et al 1986;  usage or readings from monitoring   diaries regularly.
Gong et al 1988;  devices (eg, peak-ﬂ  ow meter) or thera 
Hatton et al 1996)  peutic response or symptoms in a diary.
In-depth, structured or semi-  Interviews are conducted by a trained  Data collection and analysis is time consuming; needs skills for
structured interviews  interviewer on a purposive sample  interviewing; use sociological theories for data analysis and
(Dolce et al 1991;  based on an interview guide, which  interpretation; ﬁ  ndings are not assessed based on statistical
Earnest 2002;  are often audio-taped, transcribed and  signiﬁ  cance; investigator will have ﬂ  exibility on the depth and
Arnold et al 2006;  analyzed for content and themes.  extent of the information being gathered.
George et al 2006a, 2006c)
Direct methods 
Biological assays  Measurement of a drug or an agent   Some techniques are invasive; assays are not available for all
(Taylor et al 1984;  (eg, nicotine) or their metabolites or   medications; drug interactions might alter drug levels (eg, 
Turner et al 1995;  markers in biological ﬂ  uids.  smoking and theophylline levels).   
Clark et al 1996;     
Hatton et al 1996;     
Simmons et al 2000)     
by multiple comorbidities (Ball et al 1995; Mapel et al 2000; 
Confalonieri et al 2001; Incalzi et al 2001; George et al 
2005), patients are likely to be on complex medication regi-
mens consisting of time-contingent and prn (when required) 
oral and inhaled respiratory medications (Dolce et al 1991; 
Jackevicius and Chapman 1997; Pauwels et al 2001) as well 
as other medications (Chryssidis et al 1981). Over one-third 
of patients with COPD were found to use complementary 
and alternative medicines (George et al 2004, 2005), adding 
further complexity to their already complex medication regi-
mens. Complexity of the prescribed drug regimen in COPD 
is known to increase with disease severity as well as the 
presence of comorbidities (Friedman 1995). Patients often 
need to make alterations in their drug regimen depending 
on disease severity, opportunistic respiratory tract infections 
and seasonal changes. Reduction of therapy once symptom 
control has been achieved is not normally possible, even 
though none of the existing medications for COPD has shown 
to modify the long-term decline in lung function (Pauwels 
et al 2001; Cranston et al 2005).
According to Becker and Maiman (1975), motivating 
factors, and positive modifying and enabling factors con-
tribute to adherence, while their absence or opposite effects 
could put adherence at risk. Factors found to be associated 
with adherence in COPD in various research studies could 
be incorporated into the Becker-Maiman model to explain 
adherent behavior of COPD patients (Table 2). Despite dif-
ferences between these studies in methods employed to detect 
nonadherence, cut-off values used for classifying patients 
as adherent or nonadherent, and the populations studied, 
adherence in COPD was found to be a dynamic process 
controlled by the presence or absence of motivating factors, 
and modifying and enabling factors. The validity of this 
model has been conﬁ  rmed in both qualitative and quantitative 
studies (George et al 2005, 2006a, 2006b).
Patients analyze the beneﬁ  ts in following a recommended 
treatment against the risks/cost associated with it. They are 
likely to disregard those treatments which in their experience 
have little efﬁ  cacy or if there are concerns about their safety 
or their impact on patients’ lives. Regimen complexity does 
not pose challenges to adherence in those who could ‘routin-
ize’ their medication regimen, ie, those who could incorporate 
medication taking into their unique and complex daily lives 
(Ryan and Wagner 2003; George et al 2006a). The need 
for managing a complex medication regimen could be an 
issue in patients with cognitive impairment and those with 
depressive illness, which might explain the unintentional 
deviations from the treatment recommendations observed in 
some elderly COPD patients. The poor inhalation techniques 
among patients is not surprising when health professionals 
such as doctors, respiratory therapists, nurses and pharma-
cists who are involved in educating patients on inhalation 
techniques, themselves are known to have poor knowledge 
and ability (mainly on the ‘critical steps’) to use those devices 
(Guidry et al 1992; Kesten et al 1993).
Message for health professionals 
and researchers
Many patients with COPD do not follow their treatment 
recommendations either intentionally or unintentionally. International Journal of COPD 2007:2(3) 258
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Table 2 Factors associated with medication nonadherence: Becker-Maiman model
Factor associated with adherence  Research evidence in patients with COPD
Motivations 
  •  Concern about health matters   Perceived lack of need for medications (Apter et al 1998; George et al 2005) 
    in general  have been reported among nonadherent patients.
  •  Willingness to seek and   Patients nonadherent to long-term home nebuliser were found to continue 
    accept medical direction  smoking (Turner et al 1995).
  •  Intention to comply  Running out of medications was one of the reasons for nonadherence (Dolce 
  •  Positive health activities  et al 1991)
      Patients with greater depression scores were nonadherent to regular inhaled 
      respiratory medications (Bosley et al 1995).
      Patients who had good relationship family and friends had a desire to live 
      longer and gave up smoking (George et al 2006c).
      Nonadherent subjects had greater disruption in their home and family life 
      (Turner et al 1995).
Value of illness threat reduction 
  •  Susceptibility or   Severity of respiratory symptoms and lung function predicted adherence to 
    resusceptibility (incl. belief   nebulizer (Turner et al 1995), inhaled bronchodilator (Chryssidis et al 1981), 
    in diagnosis)  and Long-term Oxygen Therapy (Pepin et al 1996). 
  •  Vulnerability to illness in   Absence of respiratory symptoms (van Grunsven et al 2000) and feeling well 
    general  (James et al 1985) were associated with nonadherence. 
  •  Extent of possible bodily   Patients made variations in their recommended management based on how 
    harm (at motivating, but not   they felt.(George et al 2005)
    inhibiting, levels)  Worsening of respiratory symptoms might have contributed to improvement 
  •  Extent of possible   in adherence to supplemental oxygen with time in individuals with 
    interference with social roles   hypoxemic COPD (Earnest 2002).
    (at motivating, but not   Greater impairment in quality of life was found to be associated with poor 
    inhibiting, levels)  adherence to treatment (Bosley et al 1996; Corden et al 1997).
  •  Presence of (or past   Poor prognosis of COPD was found to be a major demotivating factor to quit 
    experience with) symptoms  smoking (George et al 2006c).
Probability that compliant behavior  
will reduce the threat 
  •  Proposed regimen’s safety  Greater understanding about COPD and its management, and greater 
  •  Proposed regimen’s efﬁ  cacy   conﬁ  dence that the current management would keep illness under control 
    to prevent, delay or cure   were found to be associated with better adherence (George et al 2005).
    (including ‘faith in doctors   Perceived lack of beneﬁ  t derived from treatment might have inﬂ  uenced 
    and medical care’ and   discontinuation of theophylline, despite renewal of prescription (Taylor 
    ‘chance of recovery’)  et al 1984).
      Nonadherent subjects had less conﬁ  dence in long-term home nebulizer 
      treatment (Turner et al 1995).
Demographic factors  Cognitive impairment and memory loss, characteristic features of old age, 
(Very young or old)  were associated with poor adherence to medication regimens in ambulatory 
      patients (Incalzi et al 1997). 
      Elderly patients’ competence with metered-dose inhaler technique was 
      associated with their cognition (Allen and Prior 1986). 
      Getting confused about medications was an independent predictor of 
      nonadherence (George et al 2005). 
Structural factors   Increasing cost of cigarettes and affordability of smoking cessation therapies 
(Cost, duration, complexity, side   were facilitators for smoking cessation (George et al 2006c). 
effects, accessibility of regimen,   Prescription of multiple inhalation devices that need to be handled differently 
need for new patterns of behavior)  was found to confuse patients resulting in incompetent inhalation techniques 
      (van der Palen et al 1999). 
      Better adherence with oral theophylline than inhaled anti-inﬂ  ammatory 
      medications could have been due to simplicity of regimen and/or less 
      concerns about side effects (Kelloway et al 1994). 
      Side effects or concerns about side effects from medications (Dolce et al 
      1991; Earnest 2002; Dowson et al 2004; Rand et al 1995; Pepin et al 1996; 
(Continued)International Journal of COPD 2007:2(3) 259
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been a concern in the past. Health professionals should devote 
more time for patients whose nonadherence is of concern. 
Identifying the nature of nonadherence and the reasons for 
nonadherence are also critical in clinical practice along with 
its detection and quantiﬁ  cation. Multiple methods – including 
objective measures – should be employed for monitoring 
adherence in clinical practice, especially when nonadher-
ence is suspected. Electronic monitoring, though regarded 
as the ‘gold standard’ for adherence monitoring, is more 
appropriate in a clinical trial setting where the investigators 
have to ensure that patients use their drugs as prescribed and 
need to identify those patients who are not. Self-reporting 
offers a cheap, simple and easy method for assessing adher-
ent behaviors. In addition, reasons for nonadherence can 
Motivating, enabling and modifying factors related to patient, 
disease, treatment, and health care providers could inﬂ  uence 
adherence. As time evolves COPD patients become more 
health conscious due to the progression of the disease and 
increase in disease burden, resulting in improved adherence. 
However, in the short-term adherence is likely to decline 
over time, unless enhanced by feedback and reinforcement. 
Patient knowledge about the role of treatment, conﬁ  dence 
and feedback from health professionals are likely to enhance 
treatment adherence among COPD patients. 
Adherence screening on all aspects of management 
should be routinely performed in patients with COPD using 
simple and practical tools. This need exists for all patients 
with COPD including those whose nonadherence has not 
Table 2 (Continued)
Factor associated with adherence  Research evidence in patients with COPD
      George et al 2006c), and ﬁ  nding medications to be physically challenging, 
      inconvenient or unpleasant (Rand et al 1995; Pepin et al 1996; Apter et al 
      1998; Earnest 2002; George et al 2005) have been found to be associated with 
     nonadherence. 
      Interruptions or changes in routines (Dolce et al 1991), lack of time (Apter et al
      1998; van Grunsven et al 2000), and forgetting to take the dose (Apter et al 
      1998; Dolce et al 1991; Rand et al 1995; van Grunsven et al 2000) have been 
      reported as reasons for nonadherence. 
Attitudes   Adherent patients were more satisﬁ  ed with their treatment and doctors than 
(Satisfaction with visit, physician,   their nonadherent counterparts.(George et al 2005) 
other staff, clinic procedures and   Patient satisfaction with the treatment had signiﬁ  cant correlation with 
facilities)   medication adherence (Nagy and Wolfe 1984). 
      The referring doctor is known to play a key role in the uptake of pulmonary 
      rehabilitation programmes (Arnold et al 2006). 
      Metered-dose inhaler techniques were found to be better in patients who were 
      initiated on them in the hospital than by their general practitioner (Allen and 
     Prior  1986). 
Interaction   Follow-up education (Rand et al 1995; Bosley et al 1996; Pepin et al 1996; 
(length, depth, continuity, mutuality   Gallefoss et al 1999) and feedback on usage (Simmons et al 1996) have been 
of expectation, quality and type of   shown to improve medication adherence. 
doctor-patient relationship,   Smokers complained about their health professionals lacking empathy and 
physician agreement with patient,   being inconsiderate about their difﬁ  culties; however unfriendly approaches 
feedback to patient)   had prompted smoking cessation in some patients (George et al 2006c). 
      Improvement in adherence with inhaled medications over time has been 
      attributed to the improvement in patients’ knowledge and understanding 
      about their medications (Chryssidis et al 1981). 
      Instruction has been shown to improve inhalation technique (Horsley and 
     Bailie  1988). 
      Medication dumping was less in patients who were aware that their adherence 
      was being monitored (Simmons et al 2000). 
Enabling factors   Lack of effect or perceived beneﬁ  t from treatment (Pepin et al 1996; Apter et al
(Prior experience with action, illness   1998; Earnest 2002) have been shown to result in nonadherence. 
or regimen; source of advice and   Experiences from explicit or subconscious experimentation with Long Term 
referral (incl. social pressure)   Oxygen Therapy has been found to inﬂ  uence future decisions to use that 
      therapy (Earnest 2002). 
      Compromise on social status or role in the family due to the use of home 
      oxygen was found to result in nonadherence (Earnest 2002). International Journal of COPD 2007:2(3) 260
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be identiﬁ  ed using self-report, which in turn would help in 
addressing those issues. Inhaler technique assessment forms 
a key component of adherence assessment in COPD and 
should be performed periodically.
Strategies for overcoming nonadherence have to be 
formulated based on the nature and reasons for nonadher-
ence. In the event of unintentional nonadherence, especially 
in the elderly; those with complex medication regimens; and 
those with cognitive impairment, the use of adherence aids 
such as medication lists, Dosette boxes and timers should be 
promoted. Wherever possible, the recommend treatment regi-
mens should ﬁ  t into the lifestyles and limitations of patients 
and their families. Coordinating medication use with a daily 
activity; storage of medications at places closer to their use; 
and assistance/reminding systems for the timely administra-
tion of medicines and for regular supply of medicines might 
avoid unintentional nonadherence. 
Understanding patient beliefs and experiences, patient 
education focusing on the pathology of COPD and the 
role of treatment, periodic monitoring and reinforcement 
are critical for overcoming the barriers of intentional non-
adherence. The impact of patient education is likely to be 
enhanced if health professionals elicit patients’ concerns 
and disappointments about their management and address 
those issues on an individual basis. Such efforts are likely 
to enhance COPD patients’ conﬁ  dence leading to improved 
patient adherence to both medications and non-pharmaco-
logical management. When the health care professionals are 
unsure and have questionable inhalation skills, their patients 
cannot be expected to use the inhalation devices properly. 
Training in inhalation techniques and their assessment are 
critical for all health professionals involved in instruction 
and assessment of inhalation techniques for patients. New 
interventions for reducing intentional and unintentional 
nonadherence in COPD need to be developed and tested 
in large randomized controlled trials.
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